Numerous small-molecule inhibitors of the PI3K signaling pathway are being developed [14]–[16] and are progressing through Phase I/II clinical trials in adults with solid tumors, including glioma, and we are currently planning a first-in-child pediatric Phase I trial with an expansion cohort in pediatric glioblastoma. This evidence concerns the gene PIK3CA and glioblastoma.